MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-24-2636

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025

Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.

Garcia-Del-Muro Xavier, P Valderrama Begoña, Medina-Colmenero Ana, Etxaniz Olatz, Gironés Sarrió Regina, Juan-Fita María José, Costa-García Marcel, Moreno Rafael, Miras Rodríguez Isabel, Ortiz Irene, Cuéllar Andrés, Ferrer Ferran, Vigués Francesc, de Haro Piedra Roberto, Candal Gomez Arturo, Villà Salvador, Pontones José Luis, Murria Yasmina, Lendínez-Cano Guillermo, Alemany Ramon

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: The combination of radiation and immunotherapy potentiated antitumor activity in preclinical models. The purpose of this study is to explore the feasibility, safety, and efficacy of a bladder-preserving approach, including dual immune checkpoint blockade and radiotherapy, in patients with muscle-invasive bladder cancer (MIBC).

PATIENTS AND

METHODS

Patients with localized MIBC underwent transurethral resection, followed by durvalumab (1,500 mg) plus tremelimumab (75 mg) every 4 weeks for three doses and concurrent radiotherapy (64-66 Gy to bladder). Patients with residual or relapsed MIBC underwent salvage cystectomy. The primary endpoint was complete response, defined as the absence of MIBC at posttreatment biopsy. Secondary endpoints were bladder-intact disease-free survival, distant metastasis-free survival, and overall survival.

RESULTS

Thirty-two patients were enrolled at six centers. Complete response was documented in 26 (81%) patients. Two patients had residual MIBC, and four patients were not evaluated. After a median follow-up of 27 months, 2 patients underwent salvage cystectomy. The 2-year rates for bladder-intact disease-free survival, distant metastasis-free survival, and overall survival were 65%, 83%, and 84%, respectively. The 2-year estimates of non-muscle-invasive bladder relapse, MIBC, and distant metastasis were 3%, 19%, and 16%, respectively. Grade 3 to 4 toxicities were reported in 31% of patients, with diarrhea (6%) and acute kidney failure (6%) being the most frequent.

CONCLUSIONS

This multimodal approach including durvalumab plus tremelimumab with concurrent radiotherapy is feasible and safe, showing high efficacy in terms of response and eliciting bladder preservation in a large number of patients. Further research on this approach as an alternative to cystectomy is warranted.

Для цитирования: Garcia-Del-Muro Xavier, P Valderrama Begoña, Medina-Colmenero Ana, Etxaniz Olatz, Gironés Sarrió Regina, Juan-Fita María José, Costa-García Marcel, Moreno Rafael, Miras Rodríguez Isabel, Ortiz Irene, Cuéllar Andrés, Ferrer Ferran, Vigués Francesc, de Haro Piedra Roberto, Candal Gomez Arturo, Villà Salvador, Pontones José Luis, Murria Yasmina, Lendínez-Cano Guillermo, Alemany Ramon. Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. DOI: 10.1158/1078-0432.ccr-24-2636.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.